The Relationship between Ergothioneine, Allantoin and Neocortical Amyloid Load
aging and disease · 2026
DOI: 10.14336/ad.2026.0091 ↗Kurz gefasst
Fachartikel in der Zeitschrift aging and disease, 2026. Verfasst von Shaun Eslick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Macquarie Medical School, Macquarie University, Sydney, NSW, Australia.
Abstract (Originalsprache)
lzheimer’s disease (AD) is characterised by hallmark pathology of amyloid beta (Aβ) plaques and hyperphosphorylated tau neurofibrillary tangles in the brain. Ergothioneine (ET) is a potent antioxidant, and anti-inflammatory compound that has shown potential as a therapeutic for neurodegenerative disease*. Cross-sectional analyses of cognitively normal individuals aged 65-90yrs from the Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohort were stratified by amyloid status (Aβ+, SUVR >1.35). Plasma ET, its metabolites and urinary allantoin, were quantified by liquid chromatography-mass spectrometry. Plasma Aβ1-40, Aβ1-42, GFAP, and NFL were measured by SIMOA and pTau181 and pTau231 were measured via ELISA. No differences in plasma ET or metabolites were observed between AB- (n=65) and AB+ (n=35) groups. Partial correlation analysis highlighted positive correlations between allantoin, and NFL (r = 0.40, pFDR < 0.01), pTau181 (r = 0.47, pFDR < 0.01) and GFAP (r = 0.31, pFDR = 0.01). Partial correlation by subgroup, revealed positive correlations between plasma ET (r = 0.48, pFDR = 0.05) with Aβ42/40 in the AB+ group only. Evidence indicates that ET may protect the brain from oxidative damage and neuroinflammation. Higher urinary allantoin levels were associated with higher plasma AD biomarkers. Further, plasma ET levels were higher in individuals with a higher AB42/40 ratio, within the AB+ group, suggestive that high ET may potentially have neuroprotective effects. More research will be imperative to validate the significance of ET as a therapeutic for prevention of cognitive decline.
Autor:innen und Institutionen
- Macquarie Medical School, Macquarie University, Sydney, NSW, Australia.
- Centre of Life Sciences, Department of Biochemistry, National University of Singapore, Singapore.
- Florey Institute, University of Melbourne, Melbourne, VIC, Australia.
- School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Zitieren
APA
Eslick, S., Kee-Mun, I. C., Chatterjee, P., Jerome, S., Halliwell, B., & Martins, R. (2026). The Relationship between Ergothioneine, Allantoin and Neocortical Amyloid Load. aging and disease. https://doi.org/10.14336/ad.2026.0091
Vancouver
Eslick S, Kee-Mun IC, Chatterjee P, Jerome S, Halliwell B, Martins R. The Relationship between Ergothioneine, Allantoin and Neocortical Amyloid Load. aging and disease. 2026. doi:10.14336/ad.2026.0091
BibTeX
@article{Eslick2026,
author = {Eslick, Shaun and Kee-Mun, Irwin Cheah and Chatterjee, Pratishtha and Jerome, Sarah and Halliwell, Barry and Martins, Ralph},
title = {The Relationship between Ergothioneine, Allantoin and Neocortical Amyloid Load},
journal = {aging and disease},
year = {2026},
doi = {10.14336/ad.2026.0091}
}
EUVIMED